Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03139097 · ClinicalTrials.gov registry record
Reference Range Study for the Quantra Analyzer With the Quantra Surgical Cartridge
A clinical trial, sponsored by HemoSonics.
- Completed
- Registry status
- 158
- Enrollment target
NCT03139097: Completed study, sponsored by HemoSonics.
NCT03139097 is a clinical trial that has completed, run by HemoSonics. The registered enrollment target is 158 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03139097 has completed, sponsored by HemoSonics.
- COMPLETED
- Registry status
- 158 participants
- Enrollment target
Study Summary
This study will establish reference range intervals for the Quantra System, a next-generation diagnostic platform that provides whole blood coagulation testing at the point-of-care.
Primary Outcome
Reference range intervals determined in this study from the analysis of blood samples collected from healthy adults will serve as the initial reference ranges for the Quantra test parameters when the Surgical Cartridge is commercially available.
Interventions
- DIAGNOSTIC_TEST Quantra System
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 158 participants |
| Start Date | 2017-01-16 |
| Est. Completion | 2017-09-28 |
What the finished NCT03139097 record still lists
NCT03139097 is an observational study that tracks outcomes without assigning an intervention. The registered 158 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which Quantra System is the first listed.
NCT03139097 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03139097 about?
NCT03139097 is a clinical study titled "Reference Range Study for the Quantra Analyzer With the Quantra Surgical Cartridge". This study will establish reference range intervals for the Quantra System, a next-generation diagnostic platform that provides whole blood coagulation testing at the point-of-care.
What is the current status of trial NCT03139097?
This trial is currently completed. The enrollment target is 158 participants. The study started on 2017-01-16. Estimated completion is 2017-09-28.
What interventions are being tested in trial NCT03139097?
The interventions under investigation include: Quantra System (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT03139097?
This trial is sponsored by HemoSonics, which has 24 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04486833 · 158 participants · Phase 1
Quaratusugene Ozeplasmid (Reqorsa) and Osimertinib in Patients With Advanced Lung Cancer Who Progressed on Osimertinib
- NCT04697966 · 158 participants · NA
Mechanisms and Predictors of Change in App-Based Mindfulness Training for Adolescents
- NCT04969835 · 158 participants · Phase 1
A Study Evaluating the Safety, Pharmacokinetics and Early Efficacy of AVA6000 in Solid Tumours
- NCT05230732 · 158 participants · NA
Neuromodulation of Inflammation and Endothelial Function
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI